http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
재조합 BMP-7 유전자가 전달된 HEK 293 세포에 의한 누드 마우스에서의 뼈형성
정수연,장원태,장연실,안면환,김재룡,송인환 영남대학교 의과대학 2003 Yeungnam University Journal of Medicine Vol.20 No.2
To induce bone formation at ectopic site by tissue engineering and gene therapy, we transplanted collagen sponges containing rhBMP-7 transduced HEK 293 cells in the hypodermis of nude mice. Bone formation was investigated by histological and electron microscopic method at 3, 6, and 9 weeks after transplantation. At 9 weeks after transplantation, eosinophilic bony tissue was observed in the implanted collagen sponge and was confirmed as bone tissue by Von Kossa stain. In the transmission electron microscopic observation, the cells in newly formed bone tissue had eccentrically located nucleus and well developed rough endoplasmic reticulum (rER). Therefore, the cells were evaluated as osteoblasts. Those results suggest that it is possible to form a bone tissue in the ectopic site by transplantation of rhBMP-7 transduced HEK 293 cells. This will be contributed to push more advanced gene therapy for bone formation. However, the HEK 293 cell is unable to apply to the clinical gene therapy. Therefore it is worth to find more compatible cells for clinical application. In addition, collagen sponge is considered as an excellent scaffold and/or carrier for gene therapy and a good biomaterial for tissue engineering.
<디자인과 마케팅>융합을 통한 출판사 협동조합 'POOM' 개발 -그래픽 디자인, 제품 디자인, 공간 디자인을 중심으로-
주서역,오연수,유로운,이진민,장미정,전찬희,정인희 숙명여자대학교 디자인연구소 2017 숙명디자인학 연구 Vol.23 No.-
본 연구는 한국인의 독서 장려와 보다 효율적인 독서문화 전하를 위해 출판협동조합 브랜드 'POOM'을 개발하는 일련의 과정들을 밝히는데 그 목적이 있다. 연구의 대상은 2016년 3-6월 15주간 숙명여대 환경디자인학과 <브랜드스페이스마케팅> 수업에서 진행도니 수업의 결과물로써 4개 팀 중 1개 팀의 작업물을 정리한 것이다. 연구 범위는 4개의 주제 중 물의 'product'로 한정하였다. 연구 결과, '늘 내 품에 지닐 수 있는 책' 이라는 상징 개념으로 '품(POOM)'이라고 브랜드 네이밍하였다. 그래픽 디자인은 심플함과 속도감을 나타내는 레드 컬러로 얇은 책을 형상화한 형태를 로고에 적용, 제품 디장니은 휴대하기 편한 패키지디자인 개발, 공간디자인은 지하철 2,3,9호선으로 선정하고 각 호선의 특성을 기반으로 브랜드 컬러로 하여, 각 호선에 맞는 공간과 경유하는 지역의 특성을 통합적으로 브랜딩 하였다. 끝으로 본 연구는 출판협동조합의 아이덴티티를 개발함에 있어서 디자인과 마케팅을 융합하여 좀 더 체계화된 GI, PI, SI의 통합 브랜드 메뉴얼을 만드는 것에 의의가 있으며, 향후 협동조합의 통합 브랜드 디자인 개발에 있어서 그 자료로 활용될 것으로 기대한다.
전은실,김정훈,소영,이상구,조윤숙,김연수,안규리,한진석,김성권,이정상,이현순 대한내과학회 1997 대한내과학회지 Vol.53 No.3S
유육종증에서 사구체신염의 발생은 매우 드물며, 가장 흔히 동반되는 막성신염도 현재까지 20예에 불과하였다. 또한 막성신염의 일부에서 신부전이 동반된 반면 적절한 치료방법은 아직 확립되지 않다. 저자들은 국내에서 유육종증에 동반된 막성신염을 처음으로 경험하였고, 스테로이드 치료후 단백뇨의 관해를 경험하였기에 문헌고찰과 함께 이를 보고하는 바이다. Glomerulonephritis associated with sarcoidosis is very rare and membranous nephropathy is known as the most common form of glomerulonephritis in sarcoidosis. There has been no report of glomerulonephritis associated with sarcoidosis yet in Korea. A 39-year-old woman was admitted to Seoul National University Hospital in July 1993 for pretibial pitting edema and foamy urine. In October 1992, she developed pretibial pitting edema and 1cm sized painless hard skin nodules on left buttock and right breast. At admission, she had nephrotic range proteinuria and right hilar mass. Renal biopsy and mediastinoscopic lymph node biopsy showed membranous nephropathy and noncaseating granulomatous inflammation. Therefore, she diagnosed as membranous nephropathy associated with sarcoidosis and treated with oral prednisolone. Hilar mass was disappeared 1 months after steroid therapy started and proteinuria decreased to nonnephrotic range 4 months later and subsided in March 1996. We report the first case in Korea who was diagnosed as membranous nephropathy associated with sarcoidosis and was responded well to steroid.
Recent advances in the CRISPR genome editing tool set
Su Bin Moon,Do Yon Kim,Jeong-Heon Ko,Yong-Sam Kim 생화학분자생물학회 2019 Experimental and molecular medicine Vol.51 No.-
Genome editing took a dramatic turn with the development of the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated proteins (Cas) system. The CRISPR-Cas system is functionally divided into classes 1 and 2 according to the composition of the effector genes. Class 2 consists of a single effector nuclease, and routine practice of genome editing has been achieved by the development of the Class 2 CRISPR-Cas system, which includes the type II, V, and VI CRISPR-Cas systems. Types II and V can be used for DNA editing, while type VI is employed for RNA editing. CRISPR techniques induce both qualitative and quantitative alterations in gene expression via the doublestranded breakage (DSB) repair pathway, base editing, transposase-dependent DNA integration, and gene regulation using the CRISPR-dCas or type VI CRISPR system. Despite significant technical improvements, technical challenges should be further addressed, including insufficient indel and HDR efficiency, off-target activity, the large size of Cas, PAM restrictions, and immune responses. If sophisticatedly refined, CRISPR technology will harness the process of DNA rewriting, which has potential applications in therapeutics, diagnostics, and biotechnology.
Kim, Su Jae,Cha, Su Young,Kim, Ji Young,Shin, Jong Moon,Cho, Yong Chan,Lee, Seunghun,Kim, Won-Kyung,Jeong, Se-Young,Yang, Y. S.,Cho, Chae Ryong,Choi, H. W.,Jung, Myung-Hwa,Jun, Byeong-Eog,Kwon, Ki-Yon American Chemical Society 2012 The Journal of Physical Chemistry Part C Vol.116 No.22
<P>There have been many studies of ferromagnetism in ZnCoO, and the results have been controversial. Secondary phases, such as Co oxides and Co metal clusters, in ZnCoO are easily produced during treatment, but the formation conditions are not well understood. We fabricated samples under hydrogen-injection conditions at different heat-treatment temperatures and examined the conditions by using synchrotron X-ray analysis under which Co<SUB>3</SUB>O<SUB>4</SUB> appeared or was transformed into Co metal. We investigated the transforming process of the ferromagnetic origin from intrinsic to extrinsic nature via intermediate region competition by Co–H–Co and Co metal cluster and suggest conditions that induce ferromagnetic spin ordering in ZnCoO due to Co–H–Co complexes through hydrogen mediation.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jpccck/2012/jpccck.2012.116.issue-22/jp300536w/production/images/medium/jp-2012-00536w_0010.gif'></P>
( Hyun Jeong Cho ),( Kyung Don Yoo ),( Seung Hee Yang ),( Ran Hui Cha ),( Dong Ki Kim ),( Kwon Wook Joo ),( Yon Su Kim ),( Ha Jeong Lee ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: In chronic kidney disease (CKD), lymphangiogenesis is a common feature in tubulointerstitial fi brosis. Vascular endothelial growth factor (VEGF-C) is one of the most effi cient factors in lymphangiogenesis. The aim of study was to understand the role of VEGF-C in CKD progression. Methods: We recruited CKD patients (n=205) and healthy volunteers (n=52) from April 2008 to May 2012. We stratifi ed patients into three groups according to tertiles of VEGF-C levels. Primary outcome was a composite of 50% decline in GFR, doubling of creatinine, progression to end-stage renal disease (ESRD), or all-cause mortality. Secondary outcome was a change of blood pressure. Results: In baseline characteristics, the mean age and gender were 58 ± 15 years and 62.4% men. Underlying causes of CKD were 19% diabetes and 61.5% hypertension. The presence of diabetes in lower VEGF-C group is signifi cantly higher than higher VEGF-C group (30.9% in lower, 14.5% in middle, 11.8% in higher; p=0.009). There were no statistically signifi cant differences in age, gender, body mass index, blood pressure, GFR and proteinuria. VEGF-C levels was not related with GFR (r=0.029, p=0.690). Lower VEGF-C level was a signifi cant predictor for poor renal survival after adjustments for age, gender, body mass index, blood pressure and GFR (Hazard ratio, 2.52; 95% confi dence intervals, 1.11-5.74; p=0.028). However, the signifi cance was lost after adjustment for diabetes. Although it was insignifi cant, lower VEGF-C levels tended to decrease renal survivals in both diabetic (p=0.213) and non-diabetic CKD patients (p=0.989). There were no differences between VEGF-C levels and antihypertensive drug requirements (p=0.348). Conclusion: Lower VEGF-C levels were associated with CKD progression. However, statistical signifi cance was lost after adjustment for diabetes. Diabetes may be a signi fi cant confounder. We need to evaluate the clinical relevance of VEGF-C in diabetic CKD patients.
( Eun Jeong Ko ),( Yong Kyun Kim ),( Jang-hee Cho ),( Yon Su Kim ),( Shin-wook Kang ),( Nam-ho Kim ),( Yong-lim Kim ),( Chul Woo Yang ),( Byung Ha Chung ) 대한신장학회 2020 Kidney Research and Clinical Practice Vol.39 No.2
Background: The aim of this study was to compare the effect of anemia on clinical outcomes according to age in patients with end-stage renal disease (ESRD). Methods: A total of 3,409 patients from the Clinical Research Center for ESRD were included and divided into three groups by age: age < 40 (n = 488), 40 ≤ age < 60 (n = 1,650), and age ≥ 60 (n = 1,271). We compared overall and cardiovascular mortality, and all-cause and cardiovascular hospitalization according to mean hemoglobin (Hb) concentration. Results: Among participants ≥ 60 years of age, the Hb < 10 g/dL group had greater all-cause mortality (adjusted hazard ratio [HR], 2.098; 95% confidence interval [CI], 1.567-2.808; P < 0.001) than the 10 ≤ Hb < 12 g/dL group, whereas among participants < 40 years of age, the Hb ≥ 12 g/dL group had greater mortality than the 10 ≤ Hb < 12 g/dL group. Moreover, in participants ≥ 60 years of age, the HR for all-cause hospitalization for the Hb < 10 g/dL group was significantly greater than that of the 10 ≤ Hb < 12 g/dL group (HR, 1.472; 95% CI, 1.057-2.051; P = 0.022), whereas it was significantly lower in the Hb ≥ 12 g/dL group (HR, 0.544; 95% CI, 0.362-0.820; P = 0.004) However, among participants < 40 years of age, the incidence of all-cause hospitalization did not differ according to the Hb concentration (HR, 1.273; 95% CI, 0.814-1.991; P = 0.290 for the Hb < 10 g/dL group; reference, 10 ≤ Hb < 12 g/dL; HR, 0.787; 95% CI, 0.439-1.410; P = 0.265 for Hb ≥ 12 g/dL group). Conclusion: The impact of anemia on mortality was more significant in elderly ESRD patients. Strict monitoring and management of anemia should be required for elderly ESRD patients.